The Q3 earnings season has reached its tail end with almost 85% of the companies having reported results. The 423 S&P 500 members that have reported combined account for 87.1% of the index’s total market capitalization as per the latest Earnings Preview. Total earnings for these companies are up 3.6% from the same period last year on 2.4% higher revenues, with 72.8% beating earnings estimates and 55.1% coming ahead of top-line expectations.

Healthcare comes under the broader Medical sector which is one of the seven sectors in the S&P 500 group. So far, 86.8% of the total Medical sector companies have reported third-quarter results. Total earnings for these companies are up 6.4% from the same period last year on 7.4% higher revenues, with 63% beating earnings estimates and 54.3% coming ahead of top-line expectations

Here, we take a sneak peek at four healthcare stocks scheduled to report their third-quarter figures on Nov 9:

Magellan Health, Inc. engages in the healthcare management business in the United States. The company’s Healthcare segment engages in the management of behavioral healthcare services and employee assistance program services; management of other specialty areas, including diagnostic imaging and musculoskeletal management.

Last quarter, the company posted a negative earnings surprise of 20.7%. Magellan Health carries a Zacks Rank #4 (Sell), which we caution again ahead of an earnings release. So we cannot predict an earnings beat even though the company has an Earnings ESP of +1.49% as the Most Accurate estimate stands at 68 cents, while the Zacks Consensus Estimate is pegged at 67 cents. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.

With respect to the surprise trend, Magellan Health surpassed expectations in three out of the last four quarters, with an average beat of 22.98%.

Surgery Partners, Inc. (SGRY Quick QuoteSGRY - Free Report) through its subsidiaries, operates surgical facilities in the United States. The company operates through three segments: Surgical Facility Services, Ancillary Services, and Optical Services.

Last quarter, the company posted a positive earnings surprise of 7.14%. Surgery Partners has an Earnings ESP of -7.14% as the Most Accurate estimate stands at 13 cents, while the Zacks Consensus Estimate is pegged at 14 cents. So surprise prediction is diffculy although the company carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

With respect to the surprise trend, Surgery Partners surpassed expectations in two out of the last four quarters, but has an average miss of 61.37%.

SURGERY PARTNRS Price and EPS Surprise

Intrexon Corporation operates in the synthetic biology field in the United States. The company, through a suite of proprietary and complementary technologies, designs, builds, and regulates gene programs, which are DNA sequences that consist of key genetic components.

Last quarter, the company posted a negative earnings surprise of 26.09%. Intrexon carries a Zacks Rank #3 (Hold). It has an Earnings ESP of 0.00% as both the Most Accurate estimate and the Zacks Consensus Estimate stand at a loss of 24 cents.

With respect to the surprise trend, Intrexon missed expectations in three out of the last four quarters, and has an average miss of 16.72%.

Where Do Zacks' Investment Ideas Come From?

You are welcome to download the full, up-to-the-minute list of 220 Zacks Rank #1 "Strong Buy" stocks free of charge. There is no better place to start your own stock search. Plus you can access the full list of must-avoid Zacks Rank #5 "Strong Sells" and other private research. See the stocks free >>